BPRG Bioprogress

BioProgress PLC
09 August 2007


For Immediate Release                                              9 August 2007

                                BioProgress Plc

 BioProgress to launch an enhanced anti-counterfeiting version of TabWrap(TM) at
                          CPhI, Milan in October 2007


London, UK, 9 August 2007: BioProgress plc (AIM: BPRG), the speciality
pharmaceutical and healthcare company is pleased to announce the launch of an
enhanced anti-counterfeiting version of the TabWrap(TM) enabling delivery system,
due to industry demand, at the pharmaceutical trade exhibition CPhI in Milan
Italy on 2nd-4th October 2007.

According to the World Health Organization in 2006, the counterfeiting of
medicines accounted for 5-8% of the worldwide trade in pharmaceuticals.
Counterfeiting is a global problem with false versions of products being found
within the USA, EU and Japan and the emerging markets. Estimates state that some
30% of medicines in Asia and Latin America, with 50% within Pakistan and Nigeria
are counterfeit.

The Centre for Medicines in the Public Interest in 2007 projected counterfeit
medicines sales to reach $75 billion in 2010, a 92 per cent increase from 2005.
The report estimates that the annual growth rate of counterfeiting will be
approximately 13% compared with the annual growth rate for non-counterfeit
medicines of 7.5%

A component part of the TabWrap(TM) enabling technology is the ability to dry
coat tablet cores with unique film. The Company has previously announced the
development of a new range of films adding additional efficiencies and features
to the TabWrap(TM) system. These new films have demonstrated additional benefits
of enhanced colour coding and compatibility with unique printing and laser
imprint technology which provides an improved tracking capability above that
previously integral within the TabWrap(TM) system. These markers including
complex matrix bar-codes and security inks are fully tamper evident. The system
is designed to work in conjunction with other proprietary systems as well as
other established patented packaging technologies.

Steve Martin, Chief Development Officer, BioProgress, said:

"The launch of the enhanced anti-counterfeiting TabWrap(TM) capability is an
additional strength of the enabling TabWrap(TM) system. Combined with the
EntWrap(TM) and FastWrap(TM) enhancements, along with new film systems, the
TabWrap(TM) system is multifunctional and presents an essential pharmaceutical
manufacturing technology for a wide range of customers."


Richard Trevillion, Chief Executive Officer, BioProgress, said:

"Commercial progress continues to be made with all of the Company's enabling
systems, and we look forward to further updates during the summer and the
remainder of 2007."



For further information:

BioProgress Plc                                   + 44 (0) 20 7098 9881
Richard Trevillion, CEO
Steve Martin, CDO
Hiral Patel, CFO

Buchanan Communications                           + 44 (0) 20 7466 5000
Rebecca Skye Dietrich
Mark Court



About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems.
Listed on London's AIM in May 2003, the company has over 80 patents granted or
in application within 24 patent families and has product development agreements
and strategic alliances with several global companies. As a virtually integrated
business, BioProgress has acquired sales and marketing resources within Europe
and the US as a launch mechanism for its own pharmaceutical products. The
business continues to develop innovative delivery mechanisms using its XGEL(TM)
polymer technology, replacing the need to use animal-derived gelatine in
pharmaceutical and healthcare products. For further information please go to
www.bioprogress.com




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
NRAEADPPEEDXEAE

Bioprogress (LSE:BPRG)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024

Bioprogress (LSE:BPRG)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024